Health Idea Now: Novartis asks FDA to expand Kymriah's use against blood cancer

ZURICH (Reuters) - Swiss drugmaker Novartis is seeking U.S. regulators' blessing for its Kymriah cell therapy to be used against a second form of blood cancer after winning initial approval for the treatment earlier this year.